"Before introduction of any new vaccine, you need to now the epidemiology of this disease or any disease. But, for dengue, we realised we do not have any. And, so this nationwide prevalence survey would be taken up," Director General of ICMR Soumya Swaminathan said.
She was speaking at an MoU signing function here as part of which the Indian Council of Medical Research (ICMR) and Monash University of Australia will conduct laboratory trials on a global vector-control method, whereby a naturally occurring bacteria (Wolbachia) is introduced into dengue virus-carrying mosquitoes to "inhibit" viral transmission.
Epidemiology is the study and analysis of the patterns, causes, and effects of health and disease conditions in defined populations.
A global pharmaceutical major has come up with a vaccine on dengue but it has not been introduced in India.
"That vaccine is like a booster vaccine, which means, it works if one has already got dengue infection. We need to know how many people have dengue anti-bodies...And where can we introduce the vaccine. So, before undertaking any vaccine intervention, we need to understand its epidemiology.
Swaminathan said that besides dengue prevalence survey, the government is also planning a survey to understand the disease burden of hepatitis-B and hepatitis-C.
"For treatment of hepatitis-B and hepatitis-C, we need to know the disease burden, before undertaking any intervention. Hepatitis-A is water-borne but the other two are contracted through injection or sexually transmitted.
"Our priority would be hepatitis-B and hepatitis-C as we limited dry blood spots. So, hepatitis-A burden study would eb considered accordingly," she said, adding that it would be done through National Family Health Survey.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
